An international working group of canine cognition experts has released a set of guidelines for veterinarians to use in diagnosing and monitoring canine cognitive dysfunction syndrome (CCDS), or ...

Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned down ...